Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX15-SC vs DARZALEX FASPRO in Newly Diagnosed Multiple Myeloma
NCT07477587Phase 1Recruiting
- Sponsor
- Henlius
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of daratumumab in multiple myeloma (MM) (2 arms), sponsored by Henlius. Primary endpoint: Pharmacokinetic similarity at 16 weeks. Started May 2026; status: recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07477587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07477587.